BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34482510)

  • 1. DFF40-iRGD, a novel chimeric protein with efficient cytotoxic and apoptotic effects against triple-negative breast cancer cells.
    Amrollahi-Nia R; Akbari V; Shafiee F
    Biotechnol Lett; 2021 Oct; 43(10):1967-1976. PubMed ID: 34482510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and characterization of a recombinant immunotoxin for targeted therapy of breast cancer cells: In vitro and in silico analyses.
    Barazesh M; Mohammadi S; Jalili S; Kavousipour S; Faraji SN; Mokarram P; Pirhadi S
    Life Sci; 2021 Jan; 265():118866. PubMed ID: 33301810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide.
    E M Eid E; S Alanazi A; Koosha S; A Alrasheedy A; Azam F; M Taban I; Khalilullah H; Sadiq Al-Qubaisi M; A Alshawsh M
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31337024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GM-CSF-DFF40: a novel humanized immunotoxin induces apoptosis in acute myeloid leukemia cells.
    Mathew M; Zaineb KC; Verma RS
    Apoptosis; 2013 Jul; 18(7):882-95. PubMed ID: 23529188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survivin Promoter-Driven DFF40 Gene Expression Sensitizes Melanoma Cancer Cells to Chemotherapy.
    Minaiyan G; Shafiee F; Akbari V
    Int J Toxicol; 2021; 40(4):380-387. PubMed ID: 33960240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DFF40 deficiency in cancerous T cells is implicated in chemotherapy drug sensitivity and resistance through the regulation of the apoptotic pathway.
    Kulbay M; Johnson B; Fiola S; Diaz RJ; Bernier J
    Biochem Pharmacol; 2021 Dec; 194():114801. PubMed ID: 34678222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts disease-free and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression.
    Banas T; Pitynski K; Okon K; Winiarska A
    BMC Cancer; 2018 Apr; 18(1):418. PubMed ID: 29653556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptotic DNA degradation into oligonucleosomal fragments, but not apoptotic nuclear morphology, relies on a cytosolic pool of DFF40/CAD endonuclease.
    Iglesias-Guimarais V; Gil-Guiñon E; Gabernet G; García-Belinchón M; Sánchez-Osuna M; Casanelles E; Comella JX; Yuste VJ
    J Biol Chem; 2012 Mar; 287(10):7766-79. PubMed ID: 22253444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of breast cancer cells to doxorubicin via stable cell line generation and overexpression of DFF40.
    Bagheri F; Safarian S; Eslaminejad MB; Sheibani N
    Biochem Cell Biol; 2015 Dec; 93(6):604-10. PubMed ID: 26529233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
    Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
    Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dillenia suffruticosa dichloromethane root extract induced apoptosis towards MDA-MB-231 triple-negative breast cancer cells.
    Foo JB; Saiful Yazan L; Tor YS; Wibowo A; Ismail N; Armania N; Cheah YK; Abdullah R
    J Ethnopharmacol; 2016 Jul; 187():195-204. PubMed ID: 27131434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of DNA fragmentation factor 40 nuclease activity by poly(ADP-ribose) polymerase-1.
    West JD; Ji C; Marnett LJ
    J Biol Chem; 2005 Apr; 280(15):15141-7. PubMed ID: 15703174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA fragmentation factor 40 expression in T cells confers sensibility to tributyltin-induced apoptosis.
    Kulbay M; Johnson B; Bernier J
    Toxicology; 2019 Oct; 426():152255. PubMed ID: 31401084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human lactoferrin induces apoptosis, disruption of F-actin structure and cell cycle arrest with selective cytotoxicity on human triple negative breast cancer cells.
    Iglesias-Figueroa BF; Siqueiros-Cendón TS; Gutierrez DA; Aguilera RJ; Espinoza-Sánchez EA; Arévalo-Gallegos S; Varela-Ramirez A; Rascón-Cruz Q
    Apoptosis; 2019 Aug; 24(7-8):562-577. PubMed ID: 30941553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T and B leukemic cell lines exhibit different requirements for cell death: correlation between caspase activation, DFF40/DFF45 expression, DNA fragmentation and apoptosis in T cell lines but not in Burkitt's lymphoma.
    Luciano F; Ricci JE; Herrant M; Bertolotto C; Mari B; Cousin JL; Auberger P
    Leukemia; 2002 Apr; 16(4):700-7. PubMed ID: 11960352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. iRGD mediated pH-responsive mesoporous silica enhances drug accumulation in tumors.
    Wang X; Zhao Y; Yan M; Liang X; Zhao N; Lu T
    Eur J Pharm Sci; 2024 Apr; 195():106725. PubMed ID: 38346565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy.
    Shariaty Vaziri Z; Shafiee F; Akbari V
    Biotechnol Lett; 2023 Apr; 45(4):537-550. PubMed ID: 36807722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1.
    Lao X; Liu M; Chen J; Zheng H
    PLoS One; 2013; 8(8):e72242. PubMed ID: 23977262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of non-small cell lung carcinoma apoptosis using soluble RGD-TRAIL by targeting the integrin receptor of tumor cells.
    Yao R; Sui A; Wang Z; Liu S; Zhou Q; Liu X; Zhang H
    Mol Med Rep; 2012 Dec; 6(6):1355-60. PubMed ID: 22965279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment.
    Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
    Sci Rep; 2017 Apr; 7(1):579. PubMed ID: 28373646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.